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Simple, low-cost PCR/PCR-restriction fragment length polymorphism (RFLP) assays targeting cyp51A promoter and codon 98
regions were developed for the detection of triazole-resistant Aspergillus fumigatus strains carrying TR34/L98Hmutations. The
assays were evaluated using 40 itraconazole-susceptible isolates and 35 itraconazole-resistant isolates. The prevalence of TR34/
L98Hmutations in clinical/environmental A. fumigatus isolates may now be determined easily from resource-poor settings.
Aspergillus fumigatus is the principal etiological agent of inva-sive aspergillosis (IA), a life-threatening infection in immu-
nocompromised patients. Treatment options are limited due to
the low efficacies of some antifungal drugs against clinical A. fu-
migatus isolates. Oral triazoles (itraconazole, voriconazole, and
posaconazole) exhibit excellent activities against A. fumigatus iso-
lates in vitro and are currently being used as first-line therapies in
the management and prophylaxis of IA (1). Ten years ago, ac-
quired triazole resistance among clinical A. fumigatus isolates was
rare. Clinical failures are now reported frequently, and the fre-
quency of isolation of triazole-resistant clinical A. fumigatus iso-
lates has increased in several countries (2–6). Rapid emergence of
triazole-resistant A. fumigatus isolates has been attributed to the
exposure of environmental fungi to 14-demethylase inhibitors
(DMIs) which are structurally and functionally related to clini-
cally licensed triazoles. The DMIs are widely used to control fun-
gal growth for crop plant/ornamental flower protection (7). The
occurrence of triazole-resistant A. fumigatus strains has been doc-
umented in environmental samples from some countries, with
isolation frequencies ranging from 5% to 12% (7, 8).
The molecular basis of resistance to triazoles in clinical A. fu-
migatus isolates involves point mutations at several codons in the
cyp51A gene, which encodes 14-sterol demethylase. However, a
dominant mechanism involving a 34-bp tandem repeat (TR34) in
the promoter region together with an L98H substitution (TR34/
L98H) in cyp51A has been observed in triazole-resistant isolates
recovered from environmental sources, treatment-naive subjects,
and patients under treatment (6, 9, 10). These studies have largely
been carried out at few specialized centers, possibly because these
mutations have been detected by sophisticated techniques and
expensive instruments typically involving PCR or real-time PCR
together with specific probes/molecular beacons or DNA se-
quencing (6, 10–13). In this report, we describe simple PCR/PCR-
restriction fragment length polymorphism (PCR-RFLP) assays
for rapid detection of TR34/L98H mutations in the cyp51A gene.
The study was approved by the ethical committee of the Fac-
ulty of Medicine, Kuwait University.
Reference A. fumigatus strains CBS 113.26 (carrying wild-type
sequences in the promoter region and codon 98 in cyp51A
[cyp51A98]) andVPCI1042/09 (carryingmutant [TR34/L98H] se-
quences in the promoter region and codon 98) were used for the
establishment of PCR assays. A total of 75 clinical and environ-
mental A. fumigatus isolates were used for the evaluation of the
developed methods. The background information regarding
country of origin, source of isolation, susceptibility to itracona-
zole (including MICs), and presence or absence of TR34/L98H
mutations in the cyp51A gene ofA. fumigatus isolates tested for the
performance of the molecular assays is presented in Table 1. The
details of clinical/environmental A. fumigatus isolates from
France, The Netherlands, and India that were used in this study
have also been published previously (4, 14, 15). Drug susceptibil-
ity testing (DST) of A. fumigatus isolates with itraconazole was
carried out by Etest as described elsewhere (16). Isolates with re-
duced susceptibility to itraconazole (MIC of2g/ml) were also
tested for voriconazole by a broth microdilution (M38-A2)
method (4). Isolates with MICs of 2 g/ml were considered
resistant (4).
DNA from the isolates was prepared and the internal tran-
scribed spacer (ITS) region of ribosomal DNA (rDNA) was am-
plifiedwithAFUF2 andAFUR2primers for the identification ofA.
fumigatus isolates as described previously (17). The presence or
absence of TR34 in the promoter region was determined by PCR
amplification by using AFCYPPF (5=-AATAATCGCAGCACCAC
TTC-3=) and AFCYPPR (5=-TGGTATGCTGGAACTACACCTT-
3=) primers. PCR was carried out in a total volume of 50 l con-
taining 1 AmpliTaq PCR buffer I, 1 U AmpliTaq DNA
polymerase, 4 pmol (each) of AFCYPPF and AFCYPPR primers, 2
l of DNA, and 0.1 mM each deoxynucleoside triphosphate
(dNTP). PCR cycling (total, 35 cycles) included denaturation at
95°C for 1 min, annealing at 60°C for 30 s, and extension at 72°C
for 1min. An initial denaturation step at 95°C for 5min and a final
extension step at 72°C for 10 min were also included, and the
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TABLE 1 Country of origin, source of isolation, susceptibility to itraconazole with MICs, and presence or absence of TR34/L98H mutations in the
cyp51A gene of A. fumigatus isolates
Serial
no. Isolate no. Country of origin Source of isolation
Susceptibility to ITR,d
MIC (g/ml)
TR34/L98H
mutation
1 E-296 Kuwait Outdoor air Susceptible, 0.5 No/no
2 E-149 Kuwait Outdoor air Susceptible, 0.38 No/no
3 E-288 Kuwait Hospital indoor air Susceptible, 0.75 No/no
4 E-298 Kuwait Hospital indoor air Susceptible, 0.38 No/no
5 E-256 Kuwait Hospital floor swab Susceptible, 0.75 No/no
6 E-262 Kuwait Hospital indoor air Susceptible, 0.38 No/no
7 E-267 Kuwait Hospital indoor air Susceptible, 0.38 No/no
8 E-142 Kuwait Hospital floor swab Susceptible, 0.38 No/no
9 Kw2287/09 Kuwait Clinical, sputum Susceptible, 0.75 No/no
10 Kw3468/10 Kuwait Clinical, sputum Susceptible, 0.047 No/no
11 Kw2893/10 Kuwait Clinical, sputum Susceptible, 0.75 No/no
12 Kw3068/10 Kuwait Clinical, sputum Susceptible, 0.75 No/no
13 Kw1830/08 Kuwait Clinical, wound swab Susceptible, 0.5 No/no
14 Kw3916/10 Kuwait Clinical, sputum Susceptible, 0.5 No/no
15 E-307 Kuwait Hospital indoor air Susceptible, 0.38 No/no
16 Kw2351/11 Kuwait Clinical, bronchoalveolar lavage specimen Susceptible, 0.38 No/no
17 Kw3328/10 Kuwait Clinical, sputum Susceptible, 0.75 No/no
18 Kw2349/11 Kuwait Clinical, bronchoalveolar lavage specimen Susceptible, 0.125 No/no
19 R-1 Kuwait Outdoor, soil sample Susceptible, 0.75 No/no
20 R-2 Kuwait Outdoor, soil sample Susceptible, 0.38 No/no
21 R-3 Kuwait Outdoor, soil sample Susceptible, 0.25 No/no
22 R-4 Kuwait Outdoor, soil sample Susceptible, 0.25 No/no
23 R-5 Kuwait Outdoor, soil sample Susceptible, 0.75 No/no
24 R-6 Kuwait Outdoor, soil sample Susceptible, 0.5 No/no
25 R-7 Kuwait Outdoor, soil sample Susceptible, 0.19 No/no
26 R-8 Kuwait Outdoor, soil sample Susceptible, 0.38 No/no
27 E-1 Kuwait Outdoor air Susceptible, 0.5 No/no
28 E-143 Kuwait Outdoor air Susceptible, 0.75 No/no
29 E-290 Kuwait Outdoor air Susceptible, 0.38 No/no
30 E-320 Kuwait Hospital indoor air Susceptible, 0.38 No/no
31 E-335 Kuwait Outdoor air Susceptible, 0.75 No/no
32 E-286 Kuwait Hospital indoor air Susceptible, 0.75 No/no
33 E-106 Kuwait Hospital indoor air Susceptible, 0.5 No/no
34 Kw1431/10 Kuwait Clinical, sputum Susceptible, 0.5 No/no
35 Kw2285/09 Kuwait Clinical, endotracheal aspirate Susceptible, 0.19 No/no
36 Kw2941/11 Kuwait Clinical, sputum Susceptible, 0.012 No/no
37 Kw3862/10 Kuwait Clinical, sputum Susceptible, 0.5 No/no
38 Kw1724/09 Kuwait Clinical, ear swab Susceptible, 0.25 No/no
39 Kw1787/10 Kuwait Clinical, skin swab Susceptible, 0.75 No/no
40 Kw2881/11 Kuwait Clinical, bronchoalveolar lavage specimen Susceptible, 0.38 No/no
41 E-76 Kuwait Hospital indoor air Resistant,16 Yes/yes
42 E-119 Kuwait Hospital floor swab Resistant,16 Yes/yes
43 E-218 Kuwait Outdoor air Resistant,16 Yes/yes
44 E-454 Kuwait Hospital floor swab Resistant,16 Yes/yes
45 R-15 Kuwait Soil sample Resistant,16 Yes/yes
46 R-18 Kuwait Soil sample Resistant,16 Yes/yes
47 R-44 Kuwait Soil sample Resistant,16 Yes/yes
48 10-03-18-79 India Soil sample Resistant,16 Yes/yes
49 10-03-18-83 India Soil sample Resistant,16 Yes/yes
50 10-03-19-75 India Soil sample Resistant,16 Yes/yes
51 10-03-19-73 India Soil sample Resistant,16 Yes/yes
52 10-03-18-81 India Soil sample Resistant,16 Yes/yes
53 10-03-15-27 France Clinical, sputum Resistant,16 No/noa
54 10-03-18-82 India Soil sample Resistant,16 Yes/yes
(Continued on following page)
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ampliconswere detected by use of 2%agarose gels (16).A. fumiga-
tus isolates containing TR34 in the cyp51A promoter region should
yield an amplicon of 139 bp, while isolates containing the wild-
type sequence (no tandem repeat) should yield an amplicon of 105
bp. For the detection of the wild-type sequence or the L98H
mutation at cyp51A98 inA. fumigatus isolates, DNAwas amplified
by using AFCYP98F (5=-CAAGTTCTTCTTTGCGTGCAGA-3=)
and AFCYP98R (5=-ATAAGTGGCACATGAGACTCT-3=) prim-
ers and the reaction and cycling conditions described above. A
portion (5 l) of PCR products was run on 2% agarose gels. Am-
plicons in the remaining sample (45 l) were purified with a PCR
product purification kit (Qiagen) according to instructions sup-
plied with the kit. PurifiedDNA (5l) was digested with 5 units of
AluI (NewEnglandBio-Labs) in a final volume of 25l at 37°C for
5 h, and digested products were separated by 2% agarose gels to
generate PCR-restriction fragment length polymorphism (PCR-
RFLP) patterns. The 350-bp amplicon from A. fumigatus isolates
containing the wild-type (L98) sequence (CTC, encoding Leu) in
cyp51A98 should yield three DNA fragments of 189 bp, 90 bp, and
71 bp (with the 189-bp fragment serving as the diagnostic frag-
ment), while isolates containing the L98H mutation (CAC, en-
coding His) in cyp51A98 should yield two DNA fragments of 279
bp and 71 bp (with the 279-bp fragment serving as the diagnostic
fragment). PCR amplicons from allA. fumigatus isolates were also
sequenced to confirm the results. Sequencing reactions were car-
ried out and data were analyzed as described previously (16).
In agarose gels, PCR amplification of the promoter region
yielded distinct 105-bp and 139-bp amplicons from reference A.
fumigatus isolates CBS 113.26 (containing the wild-type se-
quence) and VPCI1042/09 (containing TR34 in the promoter re-
gion), respectively. Similarly, PCR-RFLP assay of reference A. fu-
migatus isolates CBS 113.26 (containing the wild-type sequence)
and VPCI1042/09 (containing the L98H mutation at cyp51A98)
yielded three (189-bp, 90-bp, and 71-bp) and two (279-bp and
71-bp) DNA fragments, respectively, as expected. Etest data
showed that 40 A. fumigatus isolates were susceptible to itracona-
zole, while the remaining 35 isolates were resistant. All itracona-
zole-resistant isolates were also resistant to voriconazole accord-
ing to the broth microdilution assay.
PCR amplification of the cyp51A98 region from all 40 itracona-
zole-susceptible and 35 itraconazole-resistant A. fumigatus iso-
lates yielded an amplicon of 350 bp (data from 7 isolates are
shown in Fig. 1a).When the ampliconswere digestedwithAluI, 32
itraconazole-resistant isolates yielded two (279-bp and 71-bp)
fragments (data from 8 isolates are shown in Fig. 1b, lanes 1 to 8),
indicating the L98Hmutation, while 3 isolates yielded a wild-type
pattern in cyp51A98. The latter 3 isolates contained a mutation at
either codon 54 (two isolates) or codon 220 (one isolate) (Table
1). The PCR-RFLP assay with all 40 itraconazole-susceptible iso-
lates yielded three (189-bp, 90-bp, and 71-bp) fragments (data
from 6 isolates are shown in Fig. 1b, lanes 9 to 14) indicating the
wild-type sequence in cyp51A98. All 32 itraconazole-resistant iso-
lates with the L98H mutation in cyp51A98 also yielded a 139-bp
amplicon (data from 4 isolates are shown in Fig. 2, lanes 1, 2, 5,
and 6) for the promoter region, indicating the presence of TR34,
while the remaining 3 itraconazole-resistant isolates and all 40
itraconazole-susceptible isolates yielded 105-bp amplicons (data
from 4 isolates are shown in Fig. 2, lanes 3, 4, 7, and 8), indicating
the absence of the tandem-repeat sequence in the promoter re-
gion. The DNA sequencing data confirmed the results of PCR/
TABLE 1 (Continued)
Serial
no. Isolate no. Country of origin Source of isolation
Susceptibility to ITR,d
MIC (g/ml)
TR34/L98H
mutation
55 10-03-15-38 India Clinical, sputum Resistant,16 Yes/yes
56 10-03-19-72 India Soil sample Resistant,16 Yes/yes
57 10-03-18-80 India Soil sample Resistant,16 Yes/yes
58 10-03-19-74 India Soil sample Resistant,16 Yes/yes
59 10-03-15-19 France Clinical, sputum Resistant,16 No/nob
60 10-03-19-70 India Soil sample Resistant,16 Yes/yes
61 10-03-19-71 India Soil sample Resistant,16 Yes/yes
62 10-04-15-05 The Netherlands Clinical, sputum Resistant,16 Yes/yes
63 10-01-02-62 The Netherlands Clinical, sputum Resistant,16 Yes/yes
64 10-01-02-27 The Netherlands Clinical, sputum Resistant,16 Yes/yes
65 10-04-15-16 The Netherlands Clinical, sputum Resistant,16 Yes/yes
66 10-01-13-76 The Netherlands Clinical, sputum Resistant,16 No/noc
67 10-01-12-86 The Netherlands Clinical, sputum Resistant,16 Yes/yes
68 10-01-13-15 The Netherlands Clinical, sputum Resistant,16 Yes/yes
69 10-04-15-12 The Netherlands Clinical, sputum Resistant,16 Yes/yes
70 10-04-15-03 The Netherlands Clinical, sputum Resistant,16 Yes/yes
71 10-01-04-26 The Netherlands Clinical, sputum Resistant,16 Yes/yes
72 10-01-04-22 The Netherlands Clinical, sputum Resistant,16 Yes/yes
73 10-03-16-61 India Soil sample Resistant,16 Yes/yes
74 10-01-13-23 The Netherlands Clinical, sputum Resistant,16 Yes/yes
75 10-03-16-63 India Clinical, sputum Resistant,16 Yes/yes
a This isolate contained an M220R mutation in cyp51A.
b This isolate contained a G54E mutation in cyp51A.
c This isolate contained a G54W mutation in cyp51A.
d ITR, itraconazole.
Rapid Detection of TR34/L98H Mutations in cyp51A
June 2014 Volume 52 Number 6 jcm.asm.org 2225
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://jcm.asm.org/
D
ow
nloaded from
 
PCR-RFLP assays for all the isolates analyzed in this study. None
of the A. fumigatus isolates lacking TR34/L98H mutations yielded
false-positive results by PCR/PCR-RFLP assays. It is important to
emphasize here that the PCR-RFLP assay described in this study is
designed for the detection of only the L98H mutation within the
cyp51A gene. Since other cyp51Amutations are known to occur in
triazole-resistant A. fumigatus isolates, the lack of detection of the
L98Hmutation by the PCR-RFLP assay does not rule out triazole
resistance (4, 6, 18). Thus, there is a possibility of some triazole-
resistant A. fumigatus isolates yielding false-negative results by
exhibiting wild-type patterns for the promoter region and codon
98 of the cyp51A gene.
Previously, the L98H mutation has been detected by other
rapid molecular techniques, such as two (L98-specific and L98H-
specific) PCR assays (10), PCR amplification of the cyp51A98 re-
gion followed by DNA sequencing (6, 13, 18), real-time PCR with
molecular beacons (12), and melting-curve analysis of specific
probe primers with real-time PCR amplicons (11). TR34 has also
been detected by a PCR or nested PCR assay followed by DNA
sequencing (6, 13, 18), real-time PCR with molecular beacons
(12), and melting-curve analysis of PCR amplicons (11). Most of
thesemethods either are technically demanding or require expen-
sive and sophisticated instruments/probes. A simple PCR-agarose
gel assay similar to our protocol has been described previously
(10); it generated amplicons of 188 bp and 222 bp fromA. fumiga-
tus isolates containing wild-type and TR34 sequences in the pro-
moter region, respectively. However, the amplicons of 105 bp and
139 bp obtained in this study resolve better in 2%agarose gels than
the amplicons of 222 bp and 188 bp, since the distance traveled by
aDNA fragment in agarose gels is inversely proportional to the log
of its molecular weight (19).
The PCR-based methods developed in this study for rapid
identification of TR34/L98Hmutations are simple to perform, use
basic PCR and gel electrophoresis equipment that is readily avail-
able in most mycology laboratories, can be completed within 1 to
2 days, and costUS$5 per sample (excluding the cost of culture
and personnel time). The methods will help in determining the
prevalence of TR34/L98Hmutations in the cyp51A gene in clinical
and environmentalA. fumigatus isolates in resource-poor settings.
The application of these methods will also help in identifying an-
other mechanism (TR46/Y121F/T289A mutations) conferring re-
sistance to triazoles in clinical and environmental A. fumigatus
isolates described recently (20). This is because the L98H muta-
tionwithout theTR34mutationhas not beendescribed previously.
Thus, the detection of A. fumigatus isolates containing a tandem
repeat in the promoter region but lacking the L98H mutation
would indicate the presence of Y121F/T289A in the cyp51A gene,
which could be subsequently confirmed by other methods (20).
Furthermore, the simple molecular assays developed in this study
may also help in the rapid identification of TR34/L98Hmutations
in the cyp51A gene among clinical A. fumigatus isolates for proper
management of patients with IA in developing countries. How-
ever, it should be emphasized here that the simple molecular as-
says described in this study are designed only for the detection of
TR34/L98Hmutations, and triazole-resistant A. fumigatus isolates
harboring other mutations in the cyp51A gene will yield false-
negative results.
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